Manuscript Number:
21-5370R1
JOTROL, a novel formulation of resveratrol, shows beneficial effects in the 3xTg-AD mouse model
Disclosures
Shaun P. Brothers
-
Consulting Fees:I am a paid consultant of Jupiter Neurosciences, who co-authored this MS.Equity:I own shares in this private company.
Jessica Dennison
-
Nothing to Disclose
Emilie Gravel
-
Nothing to Disclose
Sabrina Hammond-Vignini
-
Nothing to Disclose
Marshall A. Hayward
-
Equity:EffRx SA, approximately 330,000 shares Jupiter Neurosciences Inc, approximately 1,000,000 shares owned and 350,000 stock options, of which approximately 200,000 are vested. The remainder of my portfolio is professionally managed and is either mutual funds, bonds, or publicly traded individual stocks, some of which are traded (bought or sold) without my direct input and on a constantly changing basis.Sponsors:I am the Chief Scientific Officer of Jupiter Neurosciences. I receive an annual salary, annual bonus, and equity options as part of my remuneration. I am a member of the Board of Directors, but I do not receive additional remuneration for this activity.Patents/RoyaltiesI am an inventor of many patents (e.g., as a co-inventor of the JOTROL formulation), all of which have been assigned to companies but I do not receive royalties on those inventions. Per my contract I retain the right to consult for third parties if there is no conflict of interest. I am not currently consulting for any third parties.
Danbing Ke
-
Nothing to Disclose
Zuomei Li
-
Nothing to Disclose
Ines Lohse
-
Nothing to Disclose
James A. Timmons
-
Equity:I own stocks in Augur Precision Medicine
Claude-Henry Volmar
-
Consulting Fees:I am a consultant for Jupiter Neurosciences Inc. I have received consulting fees for about 64 h over the last 2 years.
Claes Wahlestedt
-
Equity:Stockholder in Jupiter Neurosciences Inc.
James Wang
-
Sponsors:I’m employed by the contractor that performed part of the study sponsored by the commercial entity
